Top-Rated StocksTop-RatedNASDAQ:ASND Ascendis Pharma A/S (ASND) Stock Price, News & Analysis $119.15 +0.15 (+0.13%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$117.40▼$121.2550-Day Range$119.00▼$140.8052-Week Range$85.29▼$161.00Volume625,894 shsAverage Volume393,567 shsMarket Capitalization$6.94 billionP/E RatioN/ADividend YieldN/APrice Target$187.08 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Ascendis Pharma A/S alerts: Email Address Ascendis Pharma A/S MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside57.0% Upside$187.08 Price TargetShort InterestBearish6.34% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.04Based on 48 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.60) to ($1.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.29 out of 5 starsMedical Sector464th out of 910 stocksPharmaceutical Preparations Industry216th out of 426 stocks 4.5 Analyst's Opinion Consensus RatingAscendis Pharma A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAscendis Pharma A/S has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ascendis Pharma A/S's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.34% of the outstanding shares of Ascendis Pharma A/S have been sold short.Short Interest Ratio / Days to CoverAscendis Pharma A/S has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.Change versus previous monthShort interest in Ascendis Pharma A/S has recently increased by 5.43%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAscendis Pharma A/S does not currently pay a dividend.Dividend GrowthAscendis Pharma A/S does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ASND. Previous Next 2.2 News and Social Media Coverage News SentimentAscendis Pharma A/S has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 48 news articles for Ascendis Pharma A/S this week, compared to 5 articles on an average week.Search Interest11 people have searched for ASND on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.Percentage Held by Insiders40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Ascendis Pharma A/S's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($5.60) to ($1.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ascendis Pharma A/S is -12.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ascendis Pharma A/S is -12.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Ascendis Pharma A/S's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About Ascendis Pharma A/S Stock (NASDAQ:ASND)Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Read More ASND Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASND Stock News HeadlinesSeptember 7 at 2:10 PM | seekingalpha.comAscendis raised to outperform by Oppenheimer ahead of drug launchSeptember 7 at 3:17 AM | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Price Target Cut to $178.00 by Analysts at CitigroupSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… September 7 at 1:51 AM | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Stock Price Up 4.3% Following Analyst UpgradeSeptember 6 at 8:49 AM | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Upgraded to Hold at StockNews.comSeptember 6 at 6:23 AM | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Upgraded at OppenheimerSeptember 6 at 4:11 AM | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Receives Average Recommendation of "Buy" from BrokeragesSeptember 6 at 2:59 AM | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Price Target Cut to $170.00September 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… September 6 at 2:59 AM | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Price Target Cut to $165.00September 6 at 2:59 AM | americanbankingnews.comBank of America Boosts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $175.00September 6 at 1:07 AM | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Shares Gap Down After Analyst DowngradeSeptember 5 at 10:12 AM | seekingalpha.comAscendis Pharma A/S (ASND) Q2 2024 Earnings Call TranscriptSeptember 5 at 10:12 AM | msn.comAscendis Pharma A/S (NASDAQ:ASND) Q2 2024 Earnings Call TranscriptSeptember 5 at 5:12 AM | markets.businessinsider.comAscendis Pharma: Upgraded Price Target on Yorvipath’s Success and Long-Term Growth StrategySeptember 5 at 5:12 AM | markets.businessinsider.comAscendis Pharma (ASND) Receives a Buy from Stifel NicolausSeptember 5 at 3:33 AM | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Given New $157.00 Price Target at TD CowenSeptember 5 at 3:33 AM | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) PT Lowered to $264.00See More Headlines Receive ASND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ASND CUSIPN/A CIK1612042 Webwww.ascendispharma.com Phone(457) 022-2244Fax45-3694-4010Employees640Year FoundedN/APrice Target and Rating Average Stock Price Target$187.08 High Stock Price Target$264.00 Low Stock Price Target$140.00 Potential Upside/Downside+57.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($9.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-521,070,000.00 Net Margins-152.68% Pretax Margin-150.57% Return on Equity-16,574.15% Return on Assets-60.06% Debt Debt-to-Equity RatioN/A Current Ratio0.83 Quick Ratio0.54 Sales & Book Value Annual Sales$329.02 million Price / Sales21.09 Cash FlowN/A Price / Cash FlowN/A Book Value($2.73) per share Price / Book-43.64Miscellaneous Outstanding Shares58,231,000Free Float34,939,000Market Cap$6.94 billion OptionableOptionable Beta0.63 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Jan Moller Mikkelsen (Age 64)President, CEO, Member of Executive Board & Executive Director Mr. Scott T. Smith (Age 50)CFO, Executive VP & Member of Executive Board Ms. Lotte Sonderbjerg (Age 63)Executive VP, Chief Administrative Officer & Member of the Executive Board Mr. Michael Wolff Jensen L.L.M. (Age 53)Executive VP, Chief Legal Officer & Member of the Executive Board Mr. Mads BodenhoffSenior VP of Finance & Principal Accounting OfficerMr. Timothy J. LeeSenior Director of Investor RelationsMr. Flemming Steen Jensen (Age 63)Executive Vice President of Product Supply & Quality Dr. Kennett Sprogoe Ph.D. (Age 45)Executive VP and Head of Research & Product Development Dr. Stina Singel M.D. (Age 50)Ph.D., Executive VP & Head of Clinical Development for Oncology Mr. Joseph Kelly (Age 55)Head of U.S. Commercial of Endocrinology More ExecutivesKey CompetitorsModernaNASDAQ:MRNATeva Pharmaceutical IndustriesNYSE:TEVABioNTechNASDAQ:BNTXBeiGeneNASDAQ:BGNEGenmab A/SNASDAQ:GMABView All CompetitorsInstitutional OwnershipDriehaus Capital Management LLCSold 18,924 shares on 8/16/2024Ownership: 0.140%Quarry LPBought 1,800 shares on 8/16/2024Ownership: 0.004%Algert Global LLCBought 770 shares on 8/16/2024Ownership: 0.004%The Manufacturers Life Insurance Company Sold 6,814 shares on 8/15/2024Ownership: 0.082%Mackenzie Financial CorpSold 208 shares on 8/15/2024Ownership: 0.009%View All Institutional Transactions ASND Stock Analysis - Frequently Asked Questions How have ASND shares performed this year? Ascendis Pharma A/S's stock was trading at $125.95 at the beginning of the year. Since then, ASND shares have decreased by 5.4% and is now trading at $119.15. View the best growth stocks for 2024 here. How were Ascendis Pharma A/S's earnings last quarter? Ascendis Pharma A/S (NASDAQ:ASND) announced its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported ($1.47) EPS for the quarter, beating analysts' consensus estimates of ($2.60) by $1.13. The biotechnology company had revenue of $1.31 million for the quarter, compared to the consensus estimate of $1.60 million. Ascendis Pharma A/S had a negative trailing twelve-month return on equity of 16,574.15% and a negative net margin of 152.68%. When did Ascendis Pharma A/S IPO? Ascendis Pharma A/S (ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager. Who are Ascendis Pharma A/S's major shareholders? Ascendis Pharma A/S's top institutional shareholders include Avoro Capital Advisors LLC (7.21%), Massachusetts Financial Services Co. MA (2.94%), Sofinnova Investments Inc. (1.26%) and Fred Alger Management LLC (0.53%). How do I buy shares of Ascendis Pharma A/S? Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ascendis Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD) and Incyte (INCY). This page (NASDAQ:ASND) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
